These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 29500304

  • 1. Natalizumab: Perspectives from the Bench to Bedside.
    Shirani A, Stüve O.
    Cold Spring Harb Perspect Med; 2018 Dec 03; 8(12):. PubMed ID: 29500304
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A, Stüve O.
    J Immunol; 2017 Feb 15; 198(4):1381-1386. PubMed ID: 28167648
    [Abstract] [Full Text] [Related]

  • 3. Multiple sclerosis: Progressive multifocal leukoencephalopathy risk stratification.
    Pitarokoili K, Gold R.
    Nat Rev Neurol; 2017 Dec 15; 13(12):710-712. PubMed ID: 29146954
    [No Abstract] [Full Text] [Related]

  • 4. Fatal natalizumab-associated progressive multifocal leukoencephalopathy with initial low JCV antibody index in a multiple sclerosis patient.
    Hay M, Leguy S, Cahagne V, Lassalle N, Le Page E, Michel L.
    Rev Neurol (Paris); 2024 Jun 15; 180(6):565-567. PubMed ID: 38429158
    [No Abstract] [Full Text] [Related]

  • 5. Natalizumab treatment of multiple sclerosis: new insights.
    Delbue S, Comar M, Ferrante P.
    Immunotherapy; 2017 Jan 15; 9(2):157-171. PubMed ID: 28004598
    [Abstract] [Full Text] [Related]

  • 6. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, Stein MC, Viscidi RP, Ngo LH, Koralnik IJ.
    N Engl J Med; 2009 Sep 10; 361(11):1067-74. PubMed ID: 19741227
    [Abstract] [Full Text] [Related]

  • 7. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
    Bacchetta F, Mathias A, Schluep M, Du Pasquier R.
    Mult Scler; 2017 Feb 10; 23(2):300-303. PubMed ID: 28165319
    [Abstract] [Full Text] [Related]

  • 8. Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.
    Warnke C, Wijburg MT, Hartung HP, Killestein J, Adams O, Wattjes MP.
    J Neurol Neurosurg Psychiatry; 2017 Dec 10; 88(12):1092-1094. PubMed ID: 28490505
    [No Abstract] [Full Text] [Related]

  • 9. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R.
    Eur J Clin Invest; 2017 Feb 10; 47(2):158-166. PubMed ID: 28036121
    [Abstract] [Full Text] [Related]

  • 10. High cumulative JC virus seroconversion rate during long-term use of natalizumab.
    Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.
    Eur J Neurol; 2016 Jun 10; 23(6):1079-85. PubMed ID: 27018481
    [Abstract] [Full Text] [Related]

  • 11. Progressive multifocal leukoencephalopathy after natalizumab monotherapy.
    Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, Martin C.
    N Engl J Med; 2009 Sep 10; 361(11):1081-7. PubMed ID: 19741229
    [Abstract] [Full Text] [Related]

  • 12. Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
    Major EO.
    N Engl J Med; 2009 Sep 10; 361(11):1041-3. PubMed ID: 19741226
    [No Abstract] [Full Text] [Related]

  • 13. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 May 17; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 15. [Natalizumab can induce progressive multifocal leucoencephalopathy].
    Theódórsdóttir A, Blaabjerg M, Falah M.
    Ugeskr Laeger; 2014 Aug 25; 176(35):. PubMed ID: 25293706
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab: bench to bedside and beyond.
    Rudick R, Polman C, Clifford D, Miller D, Steinman L.
    JAMA Neurol; 2013 Feb 25; 70(2):172-82. PubMed ID: 23128399
    [Abstract] [Full Text] [Related]

  • 17. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.
    J Neuroimmunol; 2014 Dec 15; 277(1-2):6-12. PubMed ID: 25468273
    [Abstract] [Full Text] [Related]

  • 18. Use of natalizumab in multiple sclerosis: current perspectives.
    Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.
    Expert Opin Biol Ther; 2016 Sep 15; 16(9):1151-62. PubMed ID: 27413840
    [Abstract] [Full Text] [Related]

  • 19. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ, Heron M, van der Dussen D, Schneider-Hohendorf T, Murk JL.
    Acta Neurol Scand; 2017 Nov 15; 136 Suppl 201():37-44. PubMed ID: 29068484
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab.
    Berger JR.
    Drugs Today (Barc); 2006 Oct 15; 42(10):639-55. PubMed ID: 17136224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.